
Immunotherapies have transformed cancer care by enlisting the body’s own immune system to fight tumors that have evaded or hijacked normal defenses. But while checkpoint inhibitor drugs and bespoke CAR-T treatments have gained significant ground in recent years, another type of immunotherapy — cancer vaccines — have seen far less success.
New research published this week in Nature Cancer, however, suggests combining a cancer vaccine with adjuvant molecules might boost effectiveness in preventing melanoma recurrence, potentially opening the door to future combinations with other immunotherapies to vanquish cancers.